Abstract:Background: Numerous studies have shown that glucose-6-phosphate dehydrogenase (G6PD) is a tumor-promoting factor in a variety of malignancies. However, it is not entirely clear the role and the potential molecular mechanism of G6PDH in the pathogenesis or clinical prognosis of different tumors. Methods: This study first investigated the pan-tumoral expression of G6PD, then G6PD gene expression were studied in cancers, survival prognosis, tumor immunity, immunosuppressive cell infiltration, DNA methylation, gene alteration assay, and response to immunotherapy. We also investigated the function of G6PD in the development and prognosis of various cancers. Results: Our results suggest that G6PD expression was higher in tumor tissues than in normal tissues and was related to tumor stage, metastasis, and prognosis in most cancers and subtypes of the Cancer Genome Atlas. High G6PD expression is protective in a small number of cancers, including paraganglioma, pheochromocytoma, and ovarian serous cystadenocarcinoma. However, it is a risk factor for the majority of cancers. The prognosis for progression-free survival was better in people with G6PD alterations than in those without them. G6PD and immune cell infiltration were significantly positively correlated in prostate cancer, pancreatic adenocarcinoma, liver cancer, and low-grade glioma of the brain. Additionally, the degree of G6PD methylation was shown to inversely correlate with mRNA expression. The PGD, GCLM, SRXN1, TRIM16L, and TXNRD1 genes all showed significant positive correlation with G6PD expression level. The major genetic alterations were missense mutations in G6PD, and mutations at the R192C/S locus were detected in cutaneous melanoma, uterine cancer, and thyroid carcinoma. In several malignancies, G6PD expression is associated with immunological and chemotherapeutic outcomes. Conclusions: According to the study, patients who expressed more G6PD generally had better therapeutic outcomes. Our study highlights the role of G6PD in oncogenesis, detection, prognosis, and treatment planning.

IL-6/JAK2-dependent G6PD phosphorylation promotes nucleotide synthesis and supports tumor growth

O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth

Modulation of G6PD Affects Bladder Cancer Via ROS Accumulation and the AKT Pathway in Vitro.

Glucose-6-phosphate Dehydrogenase (G6PD): the Role in Tumor Progression and Immunotherapy

c-Src facilitates tumorigenesis by phosphorylating and activating G6PD

Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42

Transcription factor YY1 promotes cell proliferation by directly activating the pentose phosphate pathway.

Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1

Tyrosine Phosphorylation Activates 6-Phosphogluconate Dehydrogenase and Promotes Tumor Growth and Radiation Resistance

Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth

G6PD promotes renal cell carcinoma proliferation through positive feedback regulation of p-STAT3

PBX3 Promotes Pentose Phosphate Pathway and Colorectal Cancer Progression by Enhancing G6PD Expression.

IL-6 cooperates with G-CSF to induce protumor function of neutrophils in bone marrow by enhancing STAT3 activation

G6PD Activation in TNBC Cells Induces Macrophage Recruitment and M2 Polarization to Promote Tumor Progression

SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation

The P52-Zer6/g6pd Axis Alters Aerobic Glycolysis and Promotes Tumor Progression by Activating the Pentose Phosphate Pathway.

NeuroD1 promotes tumor cell proliferation and tumorigenesis by directly activating the pentose phosphate pathway in colorectal carcinoma

G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes

JAK2V617F Mutation Promoted IL-6 Production and Glycolysis via Mediating PKM1 Stabilization in Macrophages

JNK MAPK Regulates IFN-Stimulated Genes and Cell Adhesion in Chemoresistant, Quiescent Leukemic Cells

Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation